AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16432076
Drug: Standard-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose therapy (SDT) using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone
Trial: 16432076
Drug: Standard-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose therapy (SDT)
Trial: 16432076
Drug: Further standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further standard-dose therapy (SDT) after relapse
Trial: 11513193
Drug: Recombinant interleukin-12
RxNorm normalized name: Recombinant interleukin-12
DrugBank: Edodekin alfa (DB15631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interleukin-12 (rhIL-12) at a dose of 300 ng/kg
Trial: 8489988
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% plus epinephrine at 650 mg
Trial: 8489988
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% plus epinephrine at 500 mg
Trial: 29450877
Drug: Preoperative paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative paracetamol (IV infusion of paracetamol 15 mg kg‐1 1 h before surgery)
Trial: 29450877
Drug: Postoperative paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative paracetamol (IV infusion of paracetamol 15 mg kg‐1 in recovery room)
Trial: 29450877
Drug: Control (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (IV infusion of saline pre‐ and postoperatively)
Trial: 24357575
Drug: Multidimensional Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional Treatment Foster Care for Adolescents (MTFC‐A)
Trial: 12572529
Drug: tolterodine L-tartrate
RxNorm normalized name: Tolterodine L-tartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine L-tartrate (2 mg twice daily)
Trial: 9459246
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus 2 mL sodium bicarbonate 8.4%
Trial: 2225951
Drug: Glycopyrrolate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (2 mg every 2 hours for 6 hours)
Trial: 2225951
Drug: Metaproterenol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (15 mg every 2 hours for 6 hours)
Trial: 24686
Drug: Antacid suspensions
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid suspensions (liquid form)
Trial: 24686
Drug: Antacid chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid chewing tablets
Trial: 28266242
Drug: Sertraline (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (135 mg daily)
Trial: 16476843
Drug: Amlodipine+/−perindopril-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine+/−perindopril-based therapy
Trial: 16476843
Drug: Atenolol+/−thiazide-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol+/−thiazide-based therapy
Trial: 12742836
Drug: 2 hours
RxNorm normalized name: PATCH, TRANSDERMAL 72 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hours of daily patching combined with at least 1 hour per day of near visual activities
Trial: 12742836
Drug: 6 hours
RxNorm normalized name: nitroglycerin 0.6 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 hours of daily patching combined with at least 1 hour per day of near visual activities
Trial: 8603558
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA) treatment with end-to-end anastomosis
Trial: 8603558
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA) treatment with side-to-side or end-to-side anastomosis
Trial: 1419473
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (1 mg perindoprilat in 30 ml) over 1 h
Trial: 1419473
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (1 mg perindoprilat in 30 ml) over 3 h
Trial: 1419473
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (1 mg perindoprilat in 30 ml) over 6 h
Trial: 1419473
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (30 ml) over 3 h
Trial: 3965336
Drug: Bicozamycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicozamycin (500 mg four times a day for 3 weeks)
Trial: 20722847
Drug: Testosterone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (5 mg/d)
Trial: 15970828
Drug: Extended-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxybutynin (10 mg/d)
Trial: 15970828
Drug: Extended-release tolterodine
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tolterodine (4 mg/d)
Trial: 12452243
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 10 mg and lornoxicam 16 mg
Trial: 12452243
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 10 mg, lornoxicam 16 mg with 0.5% ropivacaine local skin infiltration before skin incision and 1% ropivacaine instillation before peritoneal incision
Trial: 12452243
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 10 mg, lornoxicam 16 mg with 1% ropivacaine instillation after peritoneal closure and 0.5% ropivacaine local skin infiltration before skin closure
Trial: 11563411
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (5 days high dose 1,050 mg/m2/day followed by 14 days low dose 700 mg/m2/day)
Trial: 11563411
Drug: Alternate regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate regimen (two courses of high dose therapy separated by one week)
Trial: 7580706
Drug: Decrement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrement of 1 mumol/l of uncategorised unstandardised vitamin E concentration
Trial: 2068533
Drug: Soluble interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble interleukin-2 receptors
Trial: 6117379
Drug: Oxprenolol SR
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxprenolol SR (160-320 mg/day)
Trial: 17267931
Drug: Increased support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased support through six weekly visits by a trained advisor
Trial: 11885112
Drug: Second-generation anticonvulsants
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation anticonvulsants (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide)
Trial: 11885112
Drug: First-generation anticonvulsants
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation anticonvulsants (phenobarbital, phenytoin, valproate)
Trial: 30157103
Drug: Milk supplementation
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk supplementation (20 g of protein, 2 servings daily)
Trial: 30157103
Drug: Native whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native whey supplementation (20 g of protein, 2 servings daily)
Trial: 25419179
Drug: Intraoperative glucose-insulin-potassium
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative glucose-insulin-potassium infusion (GIK)
Trial: 25419179
Drug: Intraoperative sliding-scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative sliding-scale insulin boluses (BR)
Trial: 25419179
Drug: GLP-1 pre-treatment
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 pre-treatment with liraglutide (LG)
Trial: 23015652
Drug: Hormone levels
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone levels (LH, FSH, testosterone, inhibin B)
Trial: 20568977
Drug: iomeprol 400
RxNorm normalized name: Iomeprol 400 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol 400 mgI/ml
Trial: 8495260
Drug: Daily exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exercise regime of six exercises
Trial: 28370210
Drug: Albendazole treatment
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole treatment (three-monthly single-dose)
Trial: 25675113
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized Japanese cedar pollen extract for 5 months
Trial: 19001792
Drug: n-3 PUFA-enriched
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA-enriched fat blend (0.69 g/day)
Trial: 17283875
Drug: HES (hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES (hydroxyethyl starch 130/0.4, 60 g/L)
Trial: 3107495
Drug: Verapamil (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (480 mg)
Trial: 28332096
Drug: Paricalcitol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (3 μg)
Trial: 18165577
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with ropivacaine (1.5 mg/kg, max 150 mg)
Trial: 10786733
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 4% nebulized lignocaine
Trial: 8368636
Drug: Vaccine (1,436
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (1,436 subjects) - 1.75 mg of formaldehyde‐killed spherules of Coccidioides immitis, administered as three intramuscular injections
Trial: 8368636
Drug: Placebo (1,431
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1,431 subjects) - sterile 0.85% NaCl solution, administered as three injections
Trial: 3716812
Drug: Triazolam 0.25
RxNorm normalized name: triazolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.25 mg after 1 night of medication
Trial: 3716812
Drug: Nitrazepam 5
RxNorm normalized name: nitrazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam 5 mg after 1 night of medication
Trial: 3716812
Drug: Nitrazepam 5
RxNorm normalized name: nitrazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam 5 mg after 3 nights of medication
Trial: 3716812
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after 1 night of medication
Trial: 3716812
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after 3 nights of medication
Trial: 26959612
Drug: Whole-pelvic (WP)
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-pelvic (WP) volumetric-modulated arc therapy (VMAT) at 46.8 Gy in 26 fractions
Trial: 26959612
Drug: Prostate-only (PO)
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate-only (PO) volumetric-modulated arc therapy (VMAT)
Trial: 20093512
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 2.5 mg
Trial: 12088808
Drug: Postoperative IV
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative IV morphine
Trial: 9484821
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 160 mg t.i.d. for 8 days before each chemotherapy cycle
Trial: 8587269
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.55 g/kg/day)
Trial: 8587269
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (2 g/kg/day)
Trial: 2663900
Drug: Ritalin 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritalin 0.15 mg/kg BID
Trial: 2663900
Drug: Ritalin 0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritalin 0.35 mg/kg BID
Trial: 2663900
Drug: Ritalin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritalin (both doses)
Trial: 27806919
Drug: Drug-Coated Stent
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Coated Stent (DCS)
Trial: 27898256
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser (LLL) therapy (780 nm laser, dose of 35.0 J/cm2, for 20 sec, thrice a week, for 4 weeks)
Trial: 27898256
Drug: Physiotherapeutic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapeutic and Drug Protocol (PDP) (hot packs thrice a day for 15 min, mouth exercises twice a day, myorelaxing and anti-inflammatory drugs)
Trial: 8536300
Drug: Apomorphine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine administration
Trial: 1517428
Drug: Self‐reinforced poly‐L‐lactide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐reinforced poly‐L‐lactide (SR‐PLLA) screw
Trial: 23448581
Drug: Proactive multifactorial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive multifactorial intervention (PMI) strategy based on single‐pill amlodipine/atorvastatin (SPAA)
Trial: 15159722
Drug: Trimetazidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (60 mg/day) added to ACEI
Trial: 11681653
Drug: Easyhaler (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Easyhaler (200 microg/dose of beclomethasone dipropionate)
Trial: 11681653
Drug: pMDI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pMDI plus Volumatic spacer (250 microg/dose of beclomethasone dipropionate)
Trial: 9773796
Drug: Mean urea
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean urea reduction ratio (URR) among treatment centers, 64.9%
Trial: 9773796
Drug: Free-standing status
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free-standing status of treatment centers
Trial: 396647
Drug: Iron tablets
RxNorm normalized name: Iron 65 MG Oral Tablet [LEADER IRON TABLETS]
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron tablets (Neo‐Fer) containing 0.20 g ferrous fumarate (60 mg Fe++)
Trial: 31680064
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose of gonadotrophin
Trial: 31680064
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose of gonadotrophin (frozen embryo transfer subgroup)
Trial: 26422094
Drug: Esomeprazole 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 0.25 mg/kg
Trial: 26422094
Drug: Esomeprazole 1
RxNorm normalized name: esomeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 1 mg/kg
Trial: 23308394
Drug: Grains of
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grains of paradise extract (40 mg)
Trial: 22097200
Drug: Qianggan Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianggan Capsule (QC) for 6 months
Trial: 22097200
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (glucurone and compound vitamin B) for 6 months
Trial: 16895135
Drug: Johnstone pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Johnstone pressure splint (JPS) - administered for 30 minutes 3 days per week
Trial: 7951099
Drug: Epoetin-alpha 300
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-alpha 300 or 450 iu/kg subcutaneously thrice weekly for 2 weeks
Trial: 2085982
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin trometamol 3 g
Trial: 354147
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (500 mg daily, total dose 30 g)
Trial: 354147
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (1,000 mg daily, total dose 60 g)
Trial: 27889546
Drug: 2-L PEG-Asc
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L PEG-Asc
Trial: 14727149
Drug: Full course
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full course of oral levofloxacin (500 mg q12 h)
Trial: 14727149
Drug: Intravenous-to-oral sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous-to-oral sequential therapy (intravenous ceftriaxone 2 g q24 h with or without clarithromycin 500 mg q12 h followed by oral beta-lactam)
Trial: 14727149
Drug: Full course
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full course of oral levofloxacin
Trial: 14727149
Drug: Intravenous-to-oral sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous-to-oral sequential therapy
Trial: 11461805
Drug: Study drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug (possibly at different dosages)
Trial: 11461805
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of the study drug
Trial: 11461805
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of the study drug
Trial: 9066005
Drug: Bradykinin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bradykinin infusion in ACEI-treated patients
Trial: 9066005
Drug: Bradykinin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bradykinin infusion in placebo-treated patients
Trial: 7526067
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg idrapril
Trial: 7526067
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg idrapril
Trial: 7526067
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg idrapril
Trial: 7526067
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg idrapril (oral)
Trial: 7526067
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg captopril
Trial: 3443046
Drug: Stepronine-lysine salt
RxNorm normalized name: stepronin
DrugBank: Stepronin (DB01423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepronine-lysine salt treatment
Trial: 26754182
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied to the PC 6 acupuncture point for 14 seconds (300 mW, energy density 4 J/cm²)
Trial: 23286297
Drug: Optimized acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized acupuncture treatment
Trial: 19399583
Drug: Preoperative supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative supplement of carbohydrate and branched-chain amino acid-enriched nutrient mixture
Trial: 12529343
Drug: Platinum-based adjuvant
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based adjuvant chemotherapy
Trial: 8855176
Drug: Higher dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose, 6 MU three times per week
Trial: 8855176
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of interferon treatment for acute hepatitis C
Trial: 1891951
Drug: Conjugate vaccine
RxNorm normalized name: meningococcal conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugate vaccine (PRP-D)
Trial: 1891951
Drug: Conjugate vaccine
RxNorm normalized name: meningococcal conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugate vaccine (PRP-D or HbOC)
Trial: 1891951
Drug: Conjugate vaccines
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugate vaccines (PRP-D, HbOC, PRP-T)
Trial: 6671926
Drug: Amoxycillin (582
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (582 mg)
Trial: 6671926
Drug: Ampicillin from
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin from bacampicillin (800 mg)